BioMarin signs global patent license deal with Ascendis for TransCon CNP products

Bitget2026/09/30 20:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioMarin signed a settlement and license agreement with Ascendis covering TransCon CNP products, effective Aug. 28, 2026.
Ascendis received a non-exclusive, worldwide, transferable license to BioMarin patents for development and commercialization across current and future indications.
BioMarin will collect royalties of 20% on U.S. net sales, 18% in the EU, Brazil, South Korea through May 2030.
Pending patent litigation between the companies will be dismissed with prejudice under the agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-063981), on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioMarin signs global patent license deal with Ascendis for TransCon CNP products

You may also like

Crypto prices